Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations.
Equillium will now participate in a virtual fireside chat presentation at the SVB Leerink Virtual Global Healthcare Conference on Thursday, February 17, 2022, at 2:20 pm Eastern Time. A live webcast of the presentation will be available under the “Investors” section of the Company’s website at https://ir.equilliumbio.com/events-and-presentations. An archived replay will be available for 90 days.
Dates for the Transplantation & Cellular Meetings of the American Society of Transplantation and Cellular Therapy, and the Center for International Blood & Marrow Transplant Research, which were originally scheduled for February have been changed to April 23 – 26, 2022. The conference will take place virtually and in person at the Salt Palace Convention Center in Salt Lake City.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD) and lupus/lupus nephritis.
For more information, visit www.equilliumbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220215005469/en/
Contacts
Investor Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
619-302-4431
ir@equilliumbio.com
Media Contacts
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
